Statement: Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.
Primary_evidence: Outcome Measurement:    Best Overall Response (BOR)   Percentage of participants with best overall (objective) response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).   Time frame: Evaluations were performed every 6 weeks until progression reported between day of first participant randomized, 20 June 2007, until cut-off date, 31 July 2009 Results 1:    Arm/Group Title: Cisplatin and Cetuximab   Arm/Group Description: Cisplatin 75 milligram per square meter (mg/m^2) intravenous (IV) infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles and cetuximab initially 400 mg/m^2 followed by 250 mg/m^2 IV infusion weekly. Participants who demonstrated at least stable disease (SD) up to 6 cycles of cisplatin continued treatment with cetuximab only until progressive disease (PD) or occurrence of unacceptable toxicity.   Overall Number of Participants Analyzed: 115   Measure Type: Number   Unit of Measure: percentage of participants  20.0        (13.1 to 28.5) Results 2:    Arm/Group Title: Cisplatin   Arm/Group Description: Cisplatin 75 mg/m^2 IV infusion administered on Day 1 until every 3 weeks with a maximum of 6 cycles until the first occurrence of PD, unacceptable toxicity or withdrawal of consent.   Overall Number of Participants Analyzed: 58   Measure Type: Number   Unit of Measure: percentage of participants  10.3        (3.9 to 21.2)